GeoVax Labs, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GOVX Nasdaq 2830 www.geovax.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for GeoVax Labs, Inc.

GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses - Jun 8th, 2026 7:00 am
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation - Jun 3rd, 2026 7:00 am
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness - Jun 1st, 2026 7:15 am
Is Co-Diagnostics National Security’s Next Diagnostic Pick? - May 28th, 2026 9:00 am
Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event - May 27th, 2026 7:00 am
Why Is GOVX Stock Falling Today? - May 26th, 2026 9:45 am
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R) - May 26th, 2026 5:30 am
How The GeoVax Labs (GOVX) Story Is Shifting With Vaccine Progress And Funding Risks - May 26th, 2026 5:08 am
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms - May 20th, 2026 8:00 am
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats - May 18th, 2026 12:30 pm
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules - May 18th, 2026 10:46 am
All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy - May 15th, 2026 10:00 am
GeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation Plans - May 14th, 2026 2:00 pm
GeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold Tumors - May 13th, 2026 7:00 am
GeoVax Announces a Warrant Inducement Transaction - May 7th, 2026 6:00 am
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway - May 6th, 2026 8:00 am
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities - Apr 29th, 2026 7:00 am
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer Therapies - Apr 27th, 2026 7:00 am
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update - Apr 15th, 2026 2:07 pm
How The GeoVax Labs (GOVX) Story Is Shifting After The Rating Downgrade And Valuation Reset - Apr 14th, 2026 7:05 am